I am an epidemiologist with a long-running interest in using population-based data to inform policy and improve health. My work with HDI is rewarding and challenging, working with industry to support the development and approval of novel anti-cancer treatments by improving our understanding of patient treatment and health outcomes in a real-world setting.
Kidney Cancer Quality Performance Indicators
Routes to diagnosis and treatment of cholangiocarcinoma (AMMF)
Real-world Standing Cohorts
Principal Health Data Analyst
Craig is an epidemiologist by training and has spent the past decade analysing longitudinal population-based datasets. He started his career at University College London, researching the complex relationship between alcohol consumption and non-communicable disease, before moving on to Cambridge University to explore the role of natural experimental studies in understanding the impact of policy on behaviour.
Most recently he has moved into pharmacoepidemiology, working with HDI to develop a series of real-world standing cohorts alongside international partners. Here, cancer registration data are linked to myriad secondary datasets to describe the patient treatment pathway, survival metrics, adverse events and changes in the therapeutic landscape. Such research is vital in supporting the health technology appraisal of novel therapeutics.
Education and Awards:
University College London, 2013-16
– PhD Epidemiology and Public Health
University College London, 2010-13
– MSc Social Epidemiology
Open University, 2004-09
– BSc Social Sciences with Social Policy
Knott CS, Panter J, Foley L, Ogilvie D. Changes in the mode of travel to work and the severity of depressive symptoms: a longitudinal analysis of UK Biobank. Prev Med. 2018; 112:61-69.
Knott CS, Britton A, Bell S. Trajectories of alcohol consumption prior to the diagnosis of type 2 diabetes: a longitudinal case-cohort study. Int J Epidemiol. 2018;47(3):953-965.
Knott CS, Bell S, Britton A. Alcohol consumption and the risk of type 2 diabetes: a systematic review and dose-response meta-analsysis of more than 1.9 million individuals from 38 observations studies. Diabetes Care, 2015;38(9): 1804-1812.
Elsada, Ahmed & Zalin‐Miller, Amy & Knott, Craig & Caravotas, Leonidas. (2021). A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England. eJHaem. 2. 10.1002/jha2.214.
Ovarian Cancer Audit Feasibility Pilot Steering Group. Short-term mortality in patients with ovarian cancer. NHS Digital, Leeds; March 2022.
Nikitas FS, Shukla U, Starkie-Camejo H, Knott CS, Previously treated recurrent or advanced endometrial cancer in England: a real-world observational analysis. Eur J Cancer. [Under review]
Knott CS, Heffernan K, Nikitas FS, Shukla U, Starkie-Camejo H. 812P Demographics and survival outcomes in patients with advanced or recurrent endometrial cancer (EC) following platinum-based doublet (PBD) in the English real-world (RW) setting. Ann Oncol. 2021;32(5):S766-S767.
Elsada A, Zalin-Miller A, Knott CS, Caravotas L. A registry study of relapsed or refractory multiple myeloma pre-exposed to 3 or more therapies including a proteasome inhibitor, an immunomodulatory agent and cd38-targeted monoclonal antibody therapy in England. eJHaem 2021:1-5.
Lamy FX, Knott CS, Harnett J, Amin A, Russo LJ, Boutmy E, Verpillat P. Novel use of the England national cancer registry to describe treatment patterns and disease outcomes in patients with advanced or metastatic cancer. [Poster] Berlin: ICPE 2020; 2020 September 16-17.
Davies FJ. Knott CS, Kerr C, Adedokun L, Lockhat DM. PCN329 Utilising Public Health England Datasets to Establish a Standing Cohort of Patients with Metastatic Bladder Cancer: Initial Results and Algorithm Defining Disease Progression. Value Health. 2020;23(2):S480-S481.
Ovarian Cancer Audit Feasibility Pilot Steering Group. Geographic variation in ovarian, fallopian tube and primary peritoneal cancer treatment in England. Public Health England, London; November 2020.
Kearney M, Knott CS, Lamy FX, Harnett J, Amin A, Verpillat P. CN2 Treatment Patterns, Survival, and Healthcare Resource Use for Locally Advanced or Metastatic Renal Cell Carcinoma in England: Results of a Longitudinal Observational Cohort Study. Value Health. 2020;23(1):S4.
Kearney M, Knott CS, Lamy FX, Harnett J, Amin A, Verpillat P. PCN341 Treatment Patterns and Clinical Outcomes in Patients with Locally Advanced or Metastatic Urothelial Cancer in England: Results of a Longitudinal Observational Cohort Study. Value Health. 2020;23(1):S4.
Ovarian Cancer Audit Feasibility Pilot Steering Group. Disease Profile in England: incidence, mortality, stage and survival for ovary, fallopian tube and primary peritoneal carcinomas. Public Health England, London; January 2020.